A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Vraylar
Synonyms :
Class :
Atypical antipsychotics
Brand Name :
Vraylar
Synonyms :
Class :
Atypical antipsychotics
Safety and efficacy not establishedÂ
Refer adult dosingÂ
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4 metabolism
It may diminish the levels when combined with efavirenz by CYP3A4 metabolism
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
When naficillin combines with cariprazine, nafcillin will decrease the effect of action of cariprazine by affecting enzyme CYP3A4 metabolism.
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
may enhance the serum concentration of CYP3A4 inhibitors
may have an increased arrhythmogenic effect when combined with mequitazine
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
cariprazine: they may diminish the serum concentration of CYP3A4 Inducers
cariprazine: they may diminish the serum concentration of CYP3A4 Inducers
cariprazine: they may diminish the serum concentration of CYP3A4 Inducers
cariprazine: they may diminish the serum concentration of CYP3A4 Inducers
cariprazine: they may diminish the serum concentration of CYP3A4 Inducers
the effect of caripazine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cariprazine
may have an increased adverse effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with sulpiride
may enhance the risk of hypertension when combined with cariprazine
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may increase the levels of serum concentrations of cariprazine
may increase the levels of serum concentrations of cariprazine
may increase the levels of serum concentrations of cariprazine
may increase the levels of serum concentrations of cariprazine
may increase the levels of serum concentrations of cariprazine
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
The potential for increased CNS depression risk or seriousness occurs when cariprazine is used together with pipecuronium
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
When cariprazine is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When cariprazine is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when cariprazine is used together with fencamfamin
When cariprazine is used together with fluconazole, this leads to reduction in the cariprazine metabolism
When chlordiazepoxide is used together with cariprazine, this leads to enhanced risk or seriousness of CNS depression
When cariprazine is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
When emylcamate is used together with cariprazine, this leads to enhanced risk or seriousness of CNS depression
When cariprazine is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with cariprazine, this leads to enhanced risk or seriousness of CNS depression
may have an increased hypotensive effect when combined with anti-hypertensive agents
combining butobarbital with capriprazine may enhance the likelihood or intensity of CNS depression
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
cariprazine: it may increase the risk or severity of CNS depression
cariprazine: it may increase the risk or severity of CNS depression
cariprazine: it may increase the risk or severity of CNS depression
cariprazine: it may increase the risk or severity of CNS depression
cariprazine: it may increase the risk or severity of CNS depression
cariprazine: it may increase the risk of hypertension with indobufen
cariprazine: it may increase the risk of hypertension with moxisylyte
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
fedratinib increases the effect of cariprazine by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
it may increase the neurotoxic effect of antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
it may increase the risk of adverse effects of antipsychotic agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
Serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may enhance the serum concentration of CYP3A4 inhibitors
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the serum concentration of CYP3A4 Inhibitors
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may have an increasingly adverse effect when combined with antipsychotic agents
may have an increased CNS depression when combined with cariprazine
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may have an increased neurotoxic effect when combined with antipsychotic agents
When cariprazine is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
Adverse drug reactions:  Â
>10% Â
Schizophrenia Â
Parkinsonism (13-18%) Â
Akathisia (9-14%) Â
Insomnia (11-13%) Â
Headache (9-18%) Â
Bipolar mania Â
Parkinsonism (21-26%) Â
Constipation (6-11%) Â
Akathisia (20-21%) Â
Extrapyramidal symptoms (41-45%) Â
Nausea (11-13%) Â
Headache (13-14%) Â
1-10% Â
Decreased appetite (>1%) Â
Schizophrenia Â
Nausea (5-8%) Â
Anxiety (3-6%) Â
Dizziness (3-5%) Â
Agitation (3-5%) Â
Diarrhea (1-5%) Â
Toothache (3-6%) Â
Hypertension (2-7%) Â
Abdominal pain (3-7%) Â
Constipation (6-10%) Â
Vomiting (4-5%) Â
Pain in extremity (2-4%) Â
Cough (1-4%) Â
Somnolence (5-10%) Â
Restlessness (4-6%) Â
Dyspepsia (4-5%) Â
  Â
Pregnancy warnings:    Â
US FDA pregnancy category: N/AÂ
Lactation:Â
Excreted into human milk is UNknown Â
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.      Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.      Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.      Â
Category N: There is no data available for the drug under this categoryÂ
Patient Information Leaflet   Â
Generic Name: cariprazineÂ
Why do we use cariprazine?Â
cariprazine are an atypical antipsychotic used to treat Bipolar I Disorder and schizophrenia.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
